J.Molner AS (OTSE:MOLNR) Short-Term Debt: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OTSE:MOLNR J.Molner AS OTSE:MOLNR
40 GF Score
Price €18.90
GF Value €19.62
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is J.Molner AS Short-Term Debt?

J.Molner AS OTSE:MOLNR 40 Short-Term Debt is €0.00 Mil as of Dec. 2025. GuruFocus rates OTSE:MOLNR with a GF Score™ of 40/100 and a GF Value™ of €19.62 (Fairly Valued). The stock has 7 warning signs investors should review.

J.Molner AS's Short-Term Debt for the quarter that ended in Dec. 2025 was €0.00 Mil.

J.Molner AS's quarterly Short-Term Debt declined from Dec. 2024 (€0.26 Mil) to Jun. 2025 (€0.00 Mil) but then stayed the same from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

J.Molner AS's annual Short-Term Debt declined from Dec. 2023 (€0.27 Mil) to Dec. 2024 (€0.26 Mil) and declined from Dec. 2024 (€0.26 Mil) to Dec. 2025 (€0.00 Mil).

J.Molner AS Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

J.Molner AS Short-Term Debt Related Terms

J.Molner AS Short-Term Debt Historical Data

* Premium members only.

The historical data trend for J.Molner AS's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

J.Molner AS Short-Term Debt Chart

J.Molner AS Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
0.25 0.27 0.27 0.26 0.00

J.Molner AS Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only 0.27 0.28 0.26 0.00 0.00
OTSE:MOLNR
40GF Score
J.Molner AS OTSE:MOLNR
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.00 Mil mean?
J.Molner AS (OTSE:MOLNR) has a Short-Term Debt of €0.00 Mil as of Dec. 2025.
Is J.Molner AS's Short-Term Debt too high?
J.Molner AS's current Short-Term Debt is €0.00 Mil. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's Short-Term Debt compare to ZTS and UTHR?
J.Molner AS's Short-Term Debt of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. J.Molner AS's current Short-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.62, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current Short-Term Debt is €0.00 Mil. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current Short-Term Debt is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?

Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued. The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62. GuruFocus considers J.Molner AS to be Fairly Valued.

Key valuation signals for OTSE:MOLNR:

  • Short-Term Debt: €0.00 Mil
  • GF Value™: €19.62 vs. price of €18.90 (3.7% below fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

J.Molner AS Business Description

Address Akadeemia tee 21/5, Harju maakond, Tallinn, EST, 12618
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score

Get the complete analysis for OTSE:MOLNR

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.90
Price
€19.62
GF Value